Min Luo’s 2017 research (15) proposed a nanotechnology-based vaccine that leveraged the STING pathway to enhance anti-tumor immune responses, implicitly highlighting mitochondria’s vital role in immune cell activation and opening new avenues for CRC immunotherapy. This evidence concerns the gene STING1 and neoplasm.